For Relatives

How can T1D patients relatives
benefit from the Innodia Research

At present, the risk of family members in developing the disease is based on the detection of auto-antibodies against beta-cell proteins, that are detectable in your blood. Such antibodies are a type of protein produced by cells in the immune system that can attack healthy cells in the body because they recognize them as ‘foreign’ cells.

The risk of developing type 1 diabetes increases with the number of autoantibodies  detected. However, these autoantibodies can be present for many years before someone develops T1D. They often appear in the first few years of life, even in people who do not develop T1D until they are adults. Therefore, more fundamental research is necessary in order to find more and better biomarkers for predicting and follow-up of the disease. Such biomarkers can by identified by analyzing blood, urine and stool samples of patients with type 1 diabetes.

INNODIA is currently recruiting children and adults across Europe aged between 1 and 45 years who have been diagnosed with type 1 diabetes within the previous 6 weeks.
Furthermore we also want to analyze blood, urine and stool samples of first-degree relatives (brothers, sisters, parents or children) as we know  that  relatives share genes with their  family  member  with  type 1 diabetes and therefore may be at greater risk of developing the disease.
With INNODIA, we have as goal to collect and analyze blood samples of 300 persons between 1 and 45 years old with a first-degree family relative who has T1D (who also got diagnosed before the age of 45) and who also tested positively for the auto-antibodies in their blood.

Taking part in this study will greatly help us to understand T1D. Participation is completely voluntary. If you agree to take part you will be asked to sign a consent form. However, you are free to change your mind and leave the study at any time without giving a reason. If you choose not to take part or you want to leave the study, your future medical treatment and care will not be affected in any way.

The study consists of a first screening for the presence of auto-antibodies in first-degree relatives. If your auto-antibody test is positive, we will ask you to come to the hospital for 7 visits over a 4 year period.

INNODIA has set-up a network of Clinical Centers where patients with newly diagnosed type 1 diabetes and their relatives can participate in the study. If you are a first-degree relative from a type 1 diabetic patient, and are interested in participating in our study, just consult the map to find out where your nearest center is and get in contact to learn more about the study and how to participate.

How can I participate?

Newly diagnosed type 1 diabetic patients and their relatives are encouraged to participate in this study by taking contact with one of our Clinical Centers throughout Europe. If you like to take part in this initiative, please consult our map to select a Center most nearby and complete the registration form so we can contact you.


What happens to my samples